The public still needs to learn about biosimilars

Biosimilars pathway_0

Even though biosimilars, the copycat version of biologics, can create cost savings up to 30 percent, they are still not well used in the United States. That’s because the public, physicians, and government agencies are not yet familiar biosimilar products. There is currently only one biosimilar drug available in the US, and some are calling for the FDA to speed up the approval process.

Read the source article at Healio

About the Author

Related Posts

Leave a Reply